Fig. 3
Antitumor effects of the recombinant oncolytic adenoviruses ADVNE and ADVPPE in a colorectal cancer murine model. (A) Schematic of the mouse model. C57BL/6 mice were subcutaneously inoculated with 1 × 10⁶ MC38 cells. When the tumors reached a volume of 50–100 mm³, intratumoral injections of 3 × 10⁸ PFU of adenovirus were administered every other day for a total of three treatments. (B) Changes in subcutaneous tumor volume and survival in the MC38 subcutaneous tumor model mice following treatment with PBS or ADVCtrl were recorded every two days (n = 8 mice per group). (C) Tumor weights were measured prior to harvest and analysis via flow cytometry (n = 6 mice per group). (D) Mouse body weights were measured every two days during the survival observation period (n = 8 mice per group). (E) Blood and tumor tissues were collected on day 7 after the first virus treatment. Tumor samples (100 mg) were homogenized in 200 µl of PBS. The supernatant and serum were separated via centrifugation. qPCR was used to measure the expression of the ADV-specific gene E1A, indicating viral distribution (n = 3 biological replicates). (F-J) BALB/c mice were subcutaneously inoculated with 1 × 10⁶ CT26 cells, and the experiments described in A-E were repeated. The data are presented as the means ± SDs. NS, no significant difference; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001